PDCD1 and cancer: These and other studies suggest that miR-200a may be a good biomarker for diagnosis of different types of cancer, such as lung, bladder, ovarian or breast cancer, as well as a potential adjuvant in immunotherapy vaccines in combination with anti-PD-1 or anti-PD-L1 antibodies [91,92,93,94,95].